META-ANALYSIS OF EFFICACY OF NANOPARTICLE-BASED CHEMOTHERAPY COMPARED TO CONVENTIONAL CHEMOTHERAPY IN SOLID TUMORS
DOI:
https://doi.org/10.71000/rce00f58Keywords:
Antineoplastic Agents, Chemotherapy, , Drug Delivery Systems, Meta-Analysis, , Nanomedicine, , Solid Tumors, Nanoparticles,Abstract
Background: Solid tumors remain a leading cause of cancer-related morbidity and mortality worldwide. While conventional chemotherapy is widely used, it often suffers from systemic toxicity and limited tumor specificity. Nanoparticle-based chemotherapy has emerged as a novel strategy to overcome these limitations by enhancing drug delivery and reducing adverse effects.
Objective: To systematically evaluate and compare the clinical efficacy and safety of nanoparticle-based chemotherapy versus conventional chemotherapy in the treatment of solid tumors.
Methods: A meta-analysis was conducted following PRISMA guidelines, incorporating 27 eligible clinical studies comprising 3,124 patients. Comparative outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related toxicities. Data were pooled using random-effects models. Subgroup and sensitivity analyses were performed, and heterogeneity was assessed using the I² statistic. Publication bias was evaluated with Egger’s test.
Results: Nanoparticle-based chemotherapy significantly improved OS (HR: 0.78, 95% CI: 0.71–0.85, p < 0.001) and PFS (HR: 0.81, 95% CI: 0.73–0.89, p < 0.001) compared to conventional chemotherapy. The pooled ORR was higher in the nanoparticle group (58.3% vs. 46.7%; OR: 1.62, p < 0.001). Grade ≥3 hematologic toxicities and peripheral neuropathy were lower in the nanoparticle group (29.6% vs. 33.8%, and 17.1% vs. 25.6%, respectively). Infusion-related reactions were slightly more frequent in the nanoparticle arm.
Conclusion: Nanoparticle-based chemotherapy demonstrates superior efficacy and a more favorable safety profile compared to conventional chemotherapy in solid tumors. These findings support its growing role in modern oncologic practice and highlight the potential for nanomedicine to improve patient outcomes.
References
Jiang Y, Lin W, Zhu L. Targeted Drug Delivery for the Treatment of Blood Cancers. Molecules. 2022;27(4).
Majernikova SM. Risk and safety profile in checkpoint inhibitors on non-small-cel lung cancer: A systematic review. Hum Vaccin Immunother. 2024;20(1):2365771.
Farias G, De Souza DG, Báo S, Da Silva VCM, Machado V, Longo JF, et al. Prevention of chemotherapy-related bone loss with doxorubicin-loaded solid lipid nanoparticles. Nanomedicine. 2024:1-17.
Ossendorp F, Cruz L, Da Silva C, Peters G. The potential of multi-compound nanoparticles to bypass drug resistance in cancer. Cancer Chemotherapy and Pharmacology. 2017;80:881-94.
Wang M, Qian Z, Shi K, Hao Y, Chu B, Hu D, et al. Oxygen-generating Hybrid Polymeric Nanoparticles with Encapsulated Doxorubicin and Chlorin e6 for Trimodal Imaging-Guided Combined Chemo-Photodynamic Therapy. Theranostics. 2018;8:1558-74.
Cui Z, Shi Y, Zheng Y, Chen Z. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles. International Journal of Nanomedicine. 2018;13:319-36.
Zhang W, Zhu K, Liu Y, Zhu H, Fu Y, Zhong C, et al. Novel biomimetic mesoporous silica nanoparticle system possessing targetability and immune synergy facilitates effective solid tumor immuno-chemotherapy. Biomaterials advances. 2022;144:213229.
Russo E, Spallarossa A, Tasso B, Villa C, Brullo C. Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective. Int J Mol Sci. 2021;22(12).
Chen J, Zhu Y, Wu C, Shi J. Nanoplatform-based cascade engineering for cancer therapy. Chem Soc Rev. 2020;49(24):9057-94.
Parashar T, Kukreti G, Verma S, Singh A, Suyal J, Dobhal K, et al. Nanoparticles – A Booming Drug Delivery System in Chemotherapy. Biomedical and Pharmacology Journal. 2023.
Lepeltier E, Rijo P, Rizzolio F, Popovtzer R, Petrikaite V, Assaraf YG, et al. Nanomedicine to target multidrug resistant tumors. Drug Resist Updat. 2020;52:100704.
Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, et al. nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol. 2021;39(33):3660-70.
Nguyen KG, Vrabel MR, Mantooth SM, Hopkins JJ, Wagner ES, Gabaldon TA, et al. Localized Interleukin-12 for Cancer Immunotherapy. Front Immunol. 2020;11:575597.
Katzir I, Popovtzer R, Sadan T, Sharon Y, Motiei M. Gold nanoparticles for enhanced delivery of chemotherapy. 2024;12858:128580-.
Li M, Wang Z, Ye H, Hou W, Li H, Li J, et al. Glutathione-Activated NO-/ROS-Generation Nanoparticles to Modulate the Tumor Hypoxic Microenvironment for Enhancing the Effect of HIFU-Combined Chemotherapy. ACS applied materials & interfaces. 2021.
Ukidve A, Kim J, Zhao Z, Gao Y, Mitragotri S. Erythrocyte leveraged chemotherapy (ELeCt): Nanoparticle assembly on erythrocyte surface to combat lung metastasis. Science Advances. 2019;5.
Shi Y, van der Meel R, Chen X, Lammers T. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10(17):7921-4.
Nieva J, In G. Emerging chemotherapy agents in lung cancer: nanoparticles therapeutics for non-small cell lung cancer. Translational cancer research. 2015;4:340-55.
Delrish E, Jabbarvand M, Ghassemi F, Amoli FA, Atyabi F, Lashay A, et al. Efficacy of topotecan nanoparticles for intravitreal chemotherapy of retinoblastoma. Exp Eye Res. 2021;204:108423.
Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, et al. Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study. Ann Surg Oncol. 2024;31(8):5340-51.
Patel JP, Spiller SE, Barker ED. Drug penetration in pediatric brain tumors: Challenges and opportunities. Pediatr Blood Cancer. 2021;68(6):e28983.
Foster CH, Dave P, Sherman JH. Chemotherapy for the Management of Cerebral Metastases. Neurosurg Clin N Am. 2020;31(4):603-11.
Kovács D, Igaz N, Gopisetty MK, Kiricsi M. Cancer Therapy by Silver Nanoparticles: Fiction or Reality? Int J Mol Sci. 2022;23(2).
Swami U, McFarland TR, Nussenzveig R, Agarwal N. Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends Cancer. 2020;6(8):702-15.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Muhammad Majid Kanwar, Amna Noor , Tanveer Rasool, Hafiza samin anjum , Aleena Ashraf , Aziz Ur Rahman , Maqsood ur Rehman (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
